PedNutritionExchange provides information and access to resources for the following products from Mead Johnson Nutrition:
Enfamil Infant is a milk-based, iron-fortified formula for full-term infants 0–12 months.
Enfamil Infant offers proven* clinical outcomes in 3 key areas: growth, brain and eye, and immune system development.
* Studies compared infants fed Enfamil with DHA and ARA vs discontinued Enfamil without DHA and ARA; studied before the addition of prebiotics.
† Comparison based on whey:casein ratio of typical mature breast milk (15 days to 6 months after birth).
Enfamil A.R. is clinically proven to reduce frequent regurgitation and meets the reflux reduction guidance of the American Academy of Pediatrics.
Enfamil A.R. is designed to provide a sole source of nutrition for infants up to age 6 months, and provide a major source of nutrition until 12 months.
* Based on a published, double-blind, randomized, controlled trial of Enfamil A.R. with infants who spit up frequently (5 or more spit-ups per day) comparing frequency and volume of spit-up after feeding Enfamil A.R. to the same infants at the beginning of the study.
† Shown in Enfamil® Infant with DHA and ARA.
Nutramigen with Enflora LGG is an iron-fortified, galactose-free, hypoallergenic infant formula designed for newborns and infants who are allergic to the intact proteins in cow’s milk and soy formulas, as well as other foods. Nutramigen with Enflora LGG contains extensively hydrolyzed protein to avoid an immune system response by reducing the allergen exposure, and the probiotic LGG to help support the strength of the intestinal barrier and support digestive health. Nutramigen with Enflora LGG is also appropriate for infants with galactosemia.
Extended use of Nutramigen with Enflora LGG (or other infant formulas) as a sole source of diet is most appropriately monitored by physicians and nutritionists on a case-by-case basis, with attention to developmental as well as nutritional implications of such a dietary regimen.
* LGG is a registered trademark of Valio Ltd. † Some studies were prior to the addition of DHA, ARA and LGG.
References 1. Lothe L, Lindberg T, Jakobsson I. Cow’s milk formula as a cause of infantile colic: a double-blind study. Pediatrics. 1982;70:7-10. 2. Lothe L, Lindberg T. Cow’s milk whey protein elicits symptoms of infantile colic in colicky formula-fed infants: a double-blind crossover study. Pediatrics. 1989;83:262-266. 3. Birch EE, Hoffman DR, Uauy R, et al. Visual acuity and the essentiality of docosahexaenoic acid and arachidonic acid in the diet of term infants. Pediatr Res. 1998;44:201-209. 4. Birch EE, Garfield S, Hoffman DR, et al. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev Med Child Neurol. 2000;42:174-181. 5. Birch EE, Hoffman DR, Castañeda YS, et al. A randomized controlled trial of long-chain polyunsaturated fatty acid supplementation of formula in term infants after weaning at 6 wk of age. Am J Clin Nutr. 2002;75:570-580. 6. Hoffman DR, Birch EE, Castañeda YS, et al. Visual function in breast-fed term infants weaned to formula with or without long-chain polyunsaturates at 4 to 6 months: a randomized clinical trial. J Pediatr. 2003;142:669-677. 7. Hoffman DR, Birch EE, Castañeda YS, et al. Maturation of visual and mental function in 18-month old infants receiving dietary long-chain polyunsaturated fatty acids (LCPUFAs) [abstract]. FASEB J. 2003;17:A727-A728. Abstract 445.1. 8. Hoffman DR, Birch EE, Birch DG, et al. Impact of early dietary intake and blood lipid composition of long-chain polyunsaturated fatty acids on later visual development. J Pediatr Gastroenterol Nutr. 2000;31:540-553. 9. Birch EE, Castañeda YS, Wheaton DH, et al. Visual maturation of term infants fed long-chain polyunsaturated fatty acid-supplemented or control formula for 12 mo. Am J Clin Nutr. 2005;81:871-879. 10. Morale SE, Hoffman DR, Castañeda YS, et al. Duration of long-chain polyunsaturated fatty acids availability in the diet and visual acuity. Early Hum Dev. 2005;81:197-203. 11. Canani R, Nocerino R, Terrin G, et al. Effect of Lactobacillus GG on tolerance acquisition in infants with cow’s milk allergy: a randomized trial. J Allergy Clin Immunol. 2012;129:580-582, 582 el-5. 12. Berni Canani R, Nocerino R, Terrin G, et al. Formula selection for management of children with cow’s milk allergy influences the rate of acquisition of tolerance: a prospective multicenter study. J Pediatr. 2013;163:771-777 el.
PurAmino is an iron-fortified, hypoallergenic, amino acid-based infant and toddler formula for the dietary management of infants and toddlers with severe cow's milk protein allergy, not effectively managed by an extensively hydrolyzed formula. PurAmino is also indicated for the dietary management of infants and toddlers with multiple food protein allergies. It may also be suitable for conditions requiring an elemental diet such as protein maldigestion, malabsorption, short bowel syndrome, and eosinophilic esophagitis.
PurAmino is designed to provide a sole source of nutrition for infants up to age 6 months and provide a major source of nutrition through 24 months of age, when indicated. Normally, in feeding infants, gradual introduction of solid foods after 4–6 months of age is an important developmental as well as nutritional step. In cases of severe and multiple food allergies or intolerances, PurAmino is sometimes continued as a milk substitute in the diet of children. This and similar supplemental use of PurAmino in the diet beyond 24 months of age may make a significant contribution to maintenance of good nutrition in such patients.
When PurAmino is used as a milk substitute, the total calcium content of the diet should be assessed.
Extended use of PurAmino (or other infant formulas) as a sole source of diet is most appropriately monitored by physicians and nutritionists on a case-by-case basis, with attention to developmental as well as nutritional implications of such a dietary regimen.